The discovery of LY6E as a potential focus for cancer immunotherapy has initiated considerable research . Multiple protein agents are now developed with the purpose of selectively blocking LY6E's function and inducing an therapeutic effect in those diagnosed with multiple tumors. Obstacles remain in refining antibody targeting and addressing potent